
Aptinyx APTX
Aptinyx Gross Profit | APTX
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.56 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.56 K | 1.56 K | 1.56 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M | ||
|
FSD Pharma
HUGE
|
-1.72 M | - | 5743.5 % | $ 69.7 M | ||
|
Codexis
CDXS
|
52.8 M | $ 1.42 | 0.33 % | $ 124 M | ||
|
Dynavax Technologies Corporation
DVAX
|
15.8 M | - | - | $ 2.02 B | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Qilian International Holding Group Limited
QLI
|
6.31 M | - | -6.08 % | $ 184 M | ||
|
Happiness Biotech Group Limited
HAPP
|
2.41 M | - | 1.35 % | $ 17.8 M | ||
|
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B | ||
|
Cue Biopharma
CUE
|
3.15 M | $ 27.67 | 2.63 % | $ 2.62 B | ||
|
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Abcam plc
ABCM
|
270 M | - | - | $ 4.9 B | ||
|
Завод ДИОД
DIOD
|
325 M | - | - | - | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Editas Medicine
EDIT
|
1.63 M | $ 3.08 | 0.33 % | $ 273 M | ||
|
Ardelyx
ARDX
|
4.68 M | $ 3.71 | 1.06 % | $ 894 M | ||
|
Affimed N.V.
AFMD
|
19.8 M | - | -34.95 % | $ 21.5 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
28.6 M | $ 4.57 | 0.21 % | $ 335 K | ||
|
Assembly Biosciences
ASMB
|
79.1 K | $ 36.13 | 4.38 % | $ 405 M | ||
|
Fate Therapeutics
FATE
|
2.43 M | $ 2.42 | 0.61 % | $ 287 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
8.34 M | - | -1.58 % | $ 28.1 M | ||
|
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M | ||
|
Fortress Biotech
FBIO
|
31 M | $ 2.71 | 0.04 % | $ 75.6 M | ||
|
Anika Therapeutics
ANIK
|
63.8 M | $ 21.0 | 2.08 % | $ 301 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.94 M | - | -4.36 % | $ 27 M | ||
|
GlycoMimetics
GLYC
|
20.1 M | - | 9357.83 % | $ 1.01 B | ||
|
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 66.43 | 0.04 % | $ 12.7 B | ||
|
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B |